Latest Results

January 31, 2019

FY2018 Full Year Consolidated Financial Overview

Financial Highlight (IFRS)

Consolidated Statements of Income

(millions of yen, rounded to the nearest one million yen)

Revenues Cost of sales Marketing and distribution Research and development General and administration
579,787 (262,847) (73,706) (99,202) (19,710)
Operating profit Operating profit ratio (%) Profit before taxes Net income Basic Earnings per share (Yen)
124,323 21.4 121,449 93,079 169.08

Consolidated Balance Sheets

(millions of yen, rounded to the nearest one million yen)

Total assets Total non-current assets Total current assets Total non-current liabilities Total current liabilities
919,548 319,455 600,093 (27,802) (135,218)
Capital and reserves attributable to Chugai shareholders Investment on property, plant and equipment (billion yen) Equity ratio attributable to Chugai shareholders (%) Annual dividends per share (yen) Interim dividends per share (yen)
755,864 71.8 82.2 86.0 55.0

Revenues: 579.8 billion JPY (+45.6, +8.5% YoY)

  • Domestic sales excl. Tamiflu®: despite impact from HIP revision, slight increase due to steady sales growth of mainstay products (+0.8, +0.2%)
  • Overseas sales: increase in exports of Actemra® and Alecensa® to Roche (+33.9, +36.1%)
  • Royalties and other operating income: one-time income from transfer of long-term listed products, and from out-licensing of developed products, etc. (+17.0, +48.7%)

Cost of sales / Operating expenses (Core basis)

  • Cost of sales: the ratio to sales improved due to a change in product mix, etc. (-1.1% points, from 50.7% to 49.6%)
  • Operating expenses: overall increase mainly due to increase of research and development expenses and general administration expenses, etc. (-9.5, +5.3%)

Profits

  • IFRS results:  
    operating profit  124.3 billion JPY (+25.4, +25.7%)
    net income  93.1 billion JPY (+19.6, +26.7%)
  • Core results:  
    operating profit  130.3 billion JPY (+27.1, +26.3%)
    net income  97.3 billion JPY (+20.6, +26.9%)
    EPS  176.42 JPY (+37.74, +27.2%)

Jan-Dec 2018 Sales excluding Tamiflu®

Core Operating Income Jan-Dec

  • *Amounts are rounded to the nearest 0.1 billion yen.
    Variance and % are calculated based on amounts shown.

More Information

Quarterly Reports

  • Like
  • Tweet
  • LINE it!
  • E-mail

Financial Results

Back to top